Change of CEO for C-RAD Imaging AB

Press release 2014-09-03

        Print
| Source: C-Rad AB

Tim Thurn takes over the position as interim CEO for C-RAD Imaging AB. Kristofer Maad, who was in charge has resigned from his position. The development of GEMini™ will continue without changes.

Kristofer Maad’s employment contract will expire September 29th 2014. There are no structural changes in the GEMini Project. C-RAD will start the recruitment process for a replacement of Kristofer Maad.

 

 

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. All companies are located in Uppsala. Numbers of employees are currently 27 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.

 

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

 

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).